Company news

Kailera Therapeutics, Inc. news in 2026

Kailera Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Kailera Therapeutics to Present at ObesityWeek 2026

November 10, 2026

Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates

November 4, 2026

Kailera Therapeutics to Participate in November Investor Conferences

November 3, 2026

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

October 1, 2026

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

September 30, 2026

Kailera Therapeutics to Participate in September Investor Conferences

September 16, 2026

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 12, 2026

Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer

August 11, 2026

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535

July 6, 2026

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

June 29, 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

June 4, 2026

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

May 25, 2026

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 19, 2026

Kailera Therapeutics Announces Pricing of Initial Public Offering

April 16, 2026

Decks in 2026